KDR and urinary bladder cancer: Ramucirumab (RAM), a fully humanized IgG1 monoclonal anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody, has been shown to exhibit significant efficacy as an anti-angiogenic agent in several cancers, including non-small cell lung cancer (NSCLC), gastric cancer (GC), colorectal cancer, and bladder cancer [11–15].